Parabilis Secures $305M to Push Forward Cancer Drug Development

The funding round led by Parabilis highlights the strong biotech fundraising environment as several companies have attracted significant capital recently. These investments underpin ongoing efforts to develop innovative cancer treatments.

TCB TeamJan 8, 20264 min

Key Funding Highlights

Parabilis Medicines raised $305 million in a fresh financing round.
The proceeds aim to support late-stage testing of its lead cancer drug candidate.
Other biotech companies also saw fundraising success in the same timeframe, including Alveus Therapeutics and Diagonal Therapeutics.

Implications

This influx of capital reflects sustained investor confidence in biotech innovation, particularly in oncology drug development. Parabilis' progress to late-stage trials marks a critical step toward potential market introduction of new cancer therapies.

Source

Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug

The Catalyst Brief

Independent biotech intelligence, every week.

Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy delivered to your inbox.

Keep reading

AusperBio Raises $120 Million Series C To Push AHB-137 Through Phase 3 In Chronic Hepatitis B

Aug 29, 2026

Biohaven Licenses Kv7 Epilepsy Platform To SK Biopharmaceutical For Up To $795 Million, Bolstering Cash Ahead Of Readouts

Dr. Priya Nandakumar

All Healthcare Investment

Parabilis Secures $305M to Push Forward Cancer Drug Development

Key Funding Highlights

Implications

Source

Keep reading

AusperBio Raises $120 Million Series C To Push AHB-137 Through Phase 3 In Chronic Hepatitis B

Genentech Pays $45 Million Upfront For DualityBio ADCs, Targeting Post-Topoisomerase Resistance

JATT III Acquisition Raises $60 Million In Nasdaq IPO, Reopening A Biotech SPAC Playbook As Traditional Listings Recover

Biohaven Licenses Kv7 Epilepsy Platform To SK Biopharmaceutical For Up To $795 Million, Bolstering Cash Ahead Of Readouts